Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.

Basit Öğe Kaydı
dc.contributor.authorGadgeel, Shirish M.
dc.contributor.authorDols, Manuel Cobo
dc.contributor.authorFelip, Enriqueta
dc.contributor.authorSoria, Jean-Charles
dc.contributor.authorLee, Ki Hyeong
dc.contributor.authorLu, Shun
dc.contributor.authorGeorgoulias, Vassilis
dc.contributor.authorFulop, Andrea
dc.contributor.authorGoker, Erdem
dc.contributor.authorSyrigos, Konstantinos N.
dc.contributor.authorMorabito, Alessandro
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorGuclu, Salih Zeki
dc.contributor.authorLi, Wei
dc.contributor.authorPopat, Sanjay
dc.contributor.authorArdizzoni, Andrea
dc.contributor.authorLungershausen, Juliane
dc.contributor.authorWang, Bushi
dc.contributor.authorChand, Vikram K.
dc.contributor.authorGoss, Glenwood D.
dc.date.accessioned2019-10-27T23:00:24Z
dc.date.available2019-10-27T23:00:24Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILen_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://hdl.handle.net/11454/51995
dc.identifier.volume33en_US
dc.identifier.wosWOS:000358036901812en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAfatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu